Your Messages Inbox
Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Merck Discontinues Development of Investigational Medicine Taranabant for Obesity
Merck & Co., 10/06/08
Merck & Co., Inc. will not seek regulatory approval for taranabant, an investigational medicine, to treat obesity and is discontinuing its Phase III clinical development program for taranabant for obesity.
| Previous Article | Next Article |
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Erlotinib Warning
JAMA, 06/29/09
Astellas Names Head of Global R and D Operations
Astellas, 06/11/09
Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
Expert Opinion in Pharmacotherapy, 06/19/09
Article Search
Sponsor